| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | R Coleman | |
| P MacCallum | |||
| P2860 | cites work | Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism | Q24245782 |
| Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 | ||
| Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) | Q28292426 | ||
| Guidelines on use of vena cava filters. | Q51155511 | ||
| A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. | Q53374794 | ||
| Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry | Q57215887 | ||
| Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry | Q57215953 | ||
| Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism | Q58375752 | ||
| Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis | Q73164615 | ||
| Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy | Q79825413 | ||
| Outcomes and cost of deep venous thrombosis among patients with cancer | Q80432495 | ||
| Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials | Q31039948 | ||
| Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data | Q33178943 | ||
| Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies | Q33377479 | ||
| Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis | Q33380057 | ||
| Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study | Q33988556 | ||
| Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial | Q34249941 | ||
| The post-thrombotic syndrome: progress and pitfalls | Q34544918 | ||
| Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788523 | ||
| Cancer-associated thrombosis: focus on extended therapy with dalteparin | Q36428299 | ||
| Long-term therapy of venous thromboembolism in cancer patients | Q36614196 | ||
| American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. | Q36984787 | ||
| Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. | Q37176707 | ||
| Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials | Q37314751 | ||
| Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis | Q41097285 | ||
| Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis | Q41099975 | ||
| Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. | Q43597590 | ||
| Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry | Q43620262 | ||
| Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study | Q44086372 | ||
| Secondary prophylaxis with warfarin for venous thromboembolism | Q44548751 | ||
| Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism | Q44636976 | ||
| Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry | Q44839772 | ||
| Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial | Q44917839 | ||
| Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. | Q47194242 | ||
| Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study | Q48661559 | ||
| Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials | Q50357078 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm | Q1216998 |
| venous thromboembolism | Q9397786 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | S17-23 | |
| P577 | publication date | 2010-04-01 | |
| 2010-04-13 | |||
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Treatment and secondary prevention of venous thromboembolism in cancer | |
| P478 | volume | 102 Suppl 1 |
| Q37588677 | Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism |
| Q53160538 | Approach to venous thromboembolism in the cancer patient. |
| Q41943022 | Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence |
| Q37998004 | Cancer-related venous thromboembolic disease: current management and areas of uncertainty |
| Q38061872 | Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology. |
| Q47211898 | Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study |
| Q38938521 | Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. |
| Q38223377 | New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients |
| Q35494098 | Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes |
| Q35004732 | Standard perioperative management in gastrointestinal surgery |
| Q50091922 | Surgical Procedures and Perioperative Management for Non-small Cell Lung Cancer Complicated with Left Atrial Tumor Thrombus |
| Q36708801 | Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism |
| Q38944457 | Venous Thromboembolism in Patients Diagnosed With Lung Cancer |
Search more.